Omneity® Pellets
All-In-One Vitamin & Mineral Pellet
Topic:Vaccine
Vaccination in horses involves the administration of biological preparations designed to stimulate the equine immune system to recognize and combat specific pathogens. Vaccines are formulated to prevent or reduce the severity of infectious diseases that can affect equine health and performance. Common vaccines for horses include those for equine influenza, tetanus, equine herpesvirus, and West Nile virus. The administration schedule and type of vaccine can vary based on factors such as geographic location, age, and use of the horse. This page compiles peer-reviewed research studies and scholarly articles that explore the development, efficacy, and safety of vaccines in horses, as well as their impact on equine health management.
Antibodies in horses, mules and donkeys following monovalent vaccination against African horse sickness. A total of 256 sera collected from three species of domesticated equidae in four different Spanish provinces were examined 1-4 months after the administration of attenuated monovalent African horse sickness virus (AHSV) serotype 4 vaccine. Approximately 10% of the sera were negative by ELISA, virus neutralization, agar gel immuno-diffusion and complement fixation tests. Similar negative reactions were recorded with sera from two ponies after experimental primary vaccination. The rapid rise in antibodies in sera from these two ponies, after a second dose of vaccine, suggested they would probabl...
[Year-round antibody profile of groups of horses of a herd kept in isolation after differently terminating use of an experimental viral combination vaccine]. The commercial vaccine "Resequin F Konz." devised against viral respiratory infections of horses contains the abortigenic Equine Herpesvirus-1 (EHV-1). Therefore we had used it in our protection project of the Austrian Lipizzaners+ primarily to prevent abortions. Taking into account the recent perception that for young horses the respiratory-pathogenic EHV-4 type is essential Behringwerke Marburg added this particular virus to their market product to produce a multicomponent experimental vaccine. We examined this vaccine for its antibody induction as well as their persistence against each of i...
Role of antibody to extracellular proteins of Rhodococcus equi in protection against R. equi pneumonia in foals. Rhodococcus equi produces two exoenzymes (REE), a cholesterol oxidase in large amounts and a phospholipase C, which cause lysis of sheep red blood cells (SRBC) sensitized with Staphylococcus aureus beta toxin. Two immunization studies were done in foals to determine the role of antibody to REE in protection against R. equi pneumonia. In the first study, three foals (mean age 10 days) were vaccinated four times at 2-week intervals with over 1 million units of partially purified exoenzymes (PREE). In the second study, three foals (mean age 19 days) were administered plasma from an adult horse va...
Assessment of an immunoturbidimetric method for measuring equine serum haptoglobin concentrations. Serum haptoglobin was measured by immunoturbidity in Thoroughbreds stabled in three Newmarket yards for nine months. The mean serum haptoglobin value for horses housed in Stable 1 was 1.43 +/- 0.68 g/litre, similar to values in grazing adult ponies. The mean monthly haptoglobin values remained constant. For horses in Stable 2 there was an increase in serum haptoglobin values in June and July whereas, in Stable 3, the increases early in the training season were associated with an increase in serum viral titres. In equine serum, haptoglobin values estimated in g/litre by immunoturbidimetry were ...
Safety and efficacy of a thymidine kinase negative equine herpesvirus-1 vaccine in young horses. A drug induced equine herpesvirus-1 (EHV-1) mutant lacking thymidine kinase inducing activity was developed and evaluated as a vaccine. The safety and effectiveness of the vaccine to protect against experimentally induced EHV-1 respiratory disease were evaluated in weanling horses free of EHV-1 neutralizing antibody. The vaccine was safe when administered either intramuscularly or intravenously, and EHV-1 was not shed intranasally during the 12 days following administration. Intranasal challenge with virulent EHV-1 was used to evaluate vaccine efficacy. Following challenge, there was a signifi...
One way protection between equid herpesvirus 1 and 4 in vivo. Two groups each of six sibling ponies were exposed to sequential infections with equid herpesvirus 1 or 4 (EHV-1 or EHV-4) at four or five month intervals. Two exposures to EHV-4 did not significantly reduce virus shedding or pyrexia when the ponies were subsequently exposed to EHV-1. However, two sequential infections with EHV-1 completely protected against challenge with EHV-4. Virus neutralising antibody in each group did not increase until 21 days after primary exposure and was subtype specific. However, complement fixing antibody rose within seven days after inoculation with EHV-1, and 14...
Induction of immune response and protection from equine viral arteritis (EVA) by formalin inactivated-virus vaccine for EVA in horses. Thirty-nine horses included 3 pregnant mares were examined by inoculating with formalin inactivated-virus vaccine for EVA. Antibody response of horses after one dose vaccination was somewhat poor and 50% effective inoculum dose of the vaccine should be included 10(8.4) pfu of virus before inactivation. After 2 doses given at an interval of 4 weeks, the horses developed such high titer of SN antibody as up to 1:5,120. The SN titer declined rather rapidly, but supplemental administration of the vaccine at an interval of more than 2 months elicited a prompt antibody response and SN titers persist...
Equine rabies immune globulin: a product with an undeserved poor reputation. Four hundred nineteen patients exposed to rabies in Thailand were treated with equine rabies immune globulin (ERIG) manufactured by Sclavo of Italy, a product also licensed in the United States of America. They were followed for a minimum of 1 month after ERIG injection and rabies vaccine administration. Adverse serum sickness-like reactions were noted in 15 patients (3.58%). These were clinically acceptable and only 1 of these patients required corticosteroid therapy and short term hospitalization for serum sickness. ERIG is approximately 1/10 of the cost of human rabies immune globulin (HRIG...
[Anthrax in Chad: a zoonosis that still exists today]. An epidemic of human and animal anthrax raged in Chad mainly in the Department of Chari Baguirmi from September to December 1988, infesting more than 50% of donkeys and horses. 716 human cases have been reported, with 88 deaths. Thanks to a geographical distribution of animal and human prevalence, one sees immediately the interdependency between sanitary state of live-stock and public health. An unusual means of transmission from donkey to donkey by insects as the vector is suggested to explain the intensity of animal epidemics. Two strains of B. anthracis were isolated and described. Systemat...
Protection of yearling ponies against Strongylus vulgaris by foalhood vaccination. The long-term efficacy of an irradiation attenuated larval (L3) vaccine against Strongylus vulgaris was tested in ponies which were reared on pasture. Prior to foaling, mares were divided into two groups. One group of mares and foals received regular (eight weekly) treatment with ivermectin and the second group remained untreated. Half the foals in each pasture group were vaccinated at eight to ten weeks of age. Foals were weaned at three to four months of age and maintained on separate pastures. At eight to ten months of age, ponies were placed in box stalls and half of each treatment group w...
[Training of the immune system of foals against ERP virus infections by frequent vaccination with presently available commercial vaccines]. During 3 foaling seasons around 150 Lipizzaner foals were vaccinated against ERP with commercial vaccines and groups thereof were serotested in CF and SN for their humoral immune response. In addition, 6 horses of cheaper common breeds were vaccinated on the University premises, were continuously serologically screened and subjected to virulent nasal test infection. The live-virus vaccine Prevaccinol interfered so profoundly and up to the 20th week of life with maternal antibodies that its further use was discontinued. The inactivated vaccine Pneumabort-K proved to be of impressive immunogenic...
Observations on antibody levels associated with active and passive immunity to African horse sickness. Tests for neutralising (NT) antibodies to the nine serotypes of African horse sickness (AHS) virus on the sera of three groups of horses confirmed that an increasing number of immunisations with vaccine containing attenuated strains of serotypes 1 to 6 of the virus, leads to broader response to the various serotypes and to higher individual titres. Nevertheless some horses failed to respond to one or more serotypes despite receiving numerous immunisations and it was clear that vaccine containing only serotypes 1 to 6 could not be relied upon to induce adequate cross-immunity to serotypes 7 to ...
African horse sickness in Zimbabwe: 1972 to 1981. During the nine years from October 1972 to September 1981 African horse sickness (AHS) virus was isolated from 23 suspected cases of the disease in Zimbabwe and complement fixation antibody titres indicative of recent infection were detected in a further 49 horses. The 23 isolations belonged to seven of the nine known serotypes of AHS virus. In response to a questionnaire in 1980 the owners of 20% (1,654/8,000) of the horses in Zimbabwe indicated that they had recorded 207 cases of clinically diagnosed AHS with 107 deaths from 1975 to 1980. Fifty-six cases with 50 deaths had occurred in foals ...
A-equi-2 influenza in horses in the Republic of South Africa. In early December 1986 A-equi-2 influenza virus was isolated for the first time in the Republic of South Africa. All horses were susceptible to the highly contagious aerosol-borne orthomyxovirus resulting in widespread outbreaks of equine influenza with typical primary respiratory symptoms. Treatment consisted of rest, anti-inflammatory drugs, antibiotics and good nursing. Future protection can be obtained by vaccination.
Influenza virus ISCOMs: antibody response in animals. A monovalent experimental ISCOM vaccine has been prepared with the envelope glycoproteins haemagglutinin and neuraminidase of the equine virus strain A/Solvalla/79 (H3N8). In vaccination trials on BALB/c mice the ISCOM vaccine induced more than ten times higher serum antibody titres measured in ELISA than a corresponding experimental micelle vaccine. Similarly, in guinea-pigs the ISCOMs induced about tenfold higher haemagglutination inhibition (HI) and neuraminidase inhibition (NI) titres than a micelle vaccine or a conventional killed influenza whole virus vaccine. Horses vaccinated with a di...
[Preventative vaccination against EHV (equine herpesvirus) abortion]. From 1981 until 1987 we investigated the more detailed circumstances regarding a prophylactic vaccination in altogether 37 stud farms with a history of virus abortion. In 23 cases, in which Prevaccinol and/or Resequin were used, it was found that the following of vaccination schedule and necessary immunization programmes respectively, had considerable imperfections. In seven cases prophylactic vaccinations were not carried out or corresponding questionnaires were not answered. The fact that in the present data no case of virus abortion was observed, when the mare was vaccinated according to th...
Equine herpes myeloencephalopathy. The neurologic form of EHV-1 infection appears to be the result of central nervous system infarction caused by vasculitis, which is initiated in endothelial cells of small blood vessels. The etiologic agent is equine herpesvirus-1, subtype 1. There is some evidence to suggest that the neurologic form of the disease actually results from reactivation of a previous infection. Whether the vasculitis that causes the central nervous system injury is the direct result of the infection or an immune response to the infection has not been determined. The clinical signs are rapid in onset, nonprogressiv...
Responses of horses vaccinated with avirulent modified-live equine arteritis virus propagated in the E. Derm (NBL-6) cell line to nasal inoculation with virulent virus. Nineteen horses with no prior experience with equine arteritis virus (EAV) were inoculated IM with an avirulent live-virus vaccine against equine viral arteritis; the vaccinal virus had been passaged serially 131 times in primary cell cultures of equine kidney, 111 times in primary cell cultures of rabbit kidney, and 16 times in an equine dermis cell line (EAV HK-131/RK-111/ED-16). Three or 4 of the vaccinated horses each, along with appropriate nonvaccinated controls, were inoculated nasally with virulent EAV at each of months 3, 6, 9, 12, 18, and 24 after they were vaccinated. The following ...
Immunity and potential of vaccination. This article will focus on current information available on the equine immune response to helminth parasites as it relates to acquired resistance, hypersensitivity reactions, and vaccine development.
Genomic and antigenic comparison of an equine herpesvirus 1 (EHV 1) isolate from the 1983 Lippizan abortion storm with EHV 1 reference strains. An EHV 1 isolate from the Lippizan Stud at Piber, which caused the abortion and paresis outbreak in 1983, was investigated using 3 known subtype 1 and 2 subtype 2 strains for comparison. Broad-scale restriction enzyme analysis as well as cross-neutralization with hyperimmune sera produced in rabbits were performed, and SDS-PAGE of infected cell proteins was conducted on a limited scale. The Piber isolate was clearly classified as a subtype 1 strain of EHV 1, and showed closest resemblance in its restriction patterns with a British EHV 1 strain, which originated from an outbreak with paretic sy...
